SUMITOMO DAINIPPON PHARMA ONCOLOGY
Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute, and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology.
SUMITOMO DAINIPPON PHARMA ONCOLOGY
Social Links:
Industry:
Health Diagnostics Oncology Pharmaceutical Therapeutics
Founded:
2021-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.sdponcology.com
Total Employee:
251+
Status:
Active
Contact:
617-674-6800
Technology used in webpage:
Domain Not Resolving SPF Amazon Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS YouTube GoDaddy DNS Amazon Virginia Region Digital Ocean
Similar Organizations
Alliance for Lupus Research
The Alliance for Lupus Research is an American voluntary health organization based in New York City
BAKX Therapeutics
BAKX Therapeutics is a provider of cancer treatment.
Censa Pharmaceuticals
Censa Pharmaceuticals primary focus is the development and commercialization of therapeutics for (ultra) orphan CNS disorders.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
E-Health Now LLC
We are the first HIPAA compliant platform that focuses on optimizing cancer treatment plans for patients in China locally, on a B2B model.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Jing Medicine Technology
Jing Medicine Technology is a developing innovative therapeutics for Oncology, Immunology and CNS disorders.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Sumitomo Pharma Oncology
Sumitomo Pharma Oncology is a developer of novel cancer therapeutics.
Current Employees Featured
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-22 | Sumitomo Dainippon Pharma Oncology Appoints Jatin J. Shah, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.sdponcology.com
- Host name: ec2-3-220-214-71.compute-1.amazonaws.com
- IP address: 3.220.214.71
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Sumitomo Dainippon Pharma Oncology"
Sumitomo Dainippon Pharma Oncology - Crunchbase
Sumitomo Dainippon Pharma Oncology or SDP Oncology. Read More. Lists Featuring This Company. Edit Lists Featuring This Company Section. …See details»
Sumitomo Dainippon Pharma Oncology - VentureRadar
As a global oncology organization with teams in the U.S. and Japan, SMP Oncology is committed to the goal of advancing purposeful science by transforming new discoveries into meaningful …See details»
Sumitomo Dainippon Pharma Oncology Announces Its Formation …
Jul 1, 2020 Augmenting this effort, SDP Oncology's Global Oncology External Innovation Hub enhances collaboration with external organizations, such as academia and venture capital, to …See details»
SUMITOMO DAINIPPON PHARMA ONCOLOGY ANNOUNCES ITS …
Jul 1, 2020 Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and …See details»
Sumitomo Dainippon Pharma Oncology Announces Its Formation …
Jul 1, 2020 Through scientific persistence and a commitment to discovery, SDP Oncology is focused on advancing a diverse and purposeful pipeline that aims to positively impact …See details»
Member Spotlight: Q&A with Sumitomo Dainippon …
Feb 1, 2022 Sumitomo Dainippon Pharma Oncology, Inc. (SDP Oncology) is based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. How do your organization’s activities help patients now and into the …See details»
Sumitomo Dainippon Pharma Oncology - ContactOut
Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. …See details»
Sumitomo Dainippon Pharma Oncology announces formation …
Jul 1, 2020 Through scientific persistence and a commitment to discovery, SDP Oncology is focused on advancing a diverse and purposeful pipeline that aims to positively impact …See details»
Sumitomo Dainippon Pharma Oncology Announces First Patient …
Oct 21, 2021 As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new …See details»
Sumitomo Pharma Oncology, Inc. Profile - Medical XPRT
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with …See details»
Sumitomo Dainippon Pharma Oncology Announces …
Oct 21, 2021 Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly …See details»
Sumitomo Dainippon Pharma Oncology - VentureRadar
SDP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common …See details»
Sumitomo Dainippon Pharma Oncology Appoints Jatin J. Shah, …
Feb 22, 2022 As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new …See details»
Sumitomo Dainippon Pharma Oncology Announces Phase 3 …
Feb 9, 2021 As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries …See details»
Sumitomo Dainippon Pharma Oncology Provides Update on …
Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and …See details»
Sumitomo Dainippon Pharma Oncology Announces First Patient
Recommended Phase 2 dose (RP2D) in recurrent World Health Organization (WHO) Grade III or IV malignant glioma. The trial is being conducted in the United States and Japan. Additional …See details»
Sumitomo Dainippon Pharma Oncology | VentureRadar
SDP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common …See details»
Columbia-SDP Oncology Research Alliance
The Columbia - SDP Oncology Research Alliance ran from 2019-2022 and ... As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly …See details»
www.sdponcology.us
Www.sdponcology.usSee details»
Sumitomo Dainippon Pharma Oncology Presents New Data from ...
Apr 10, 2021 As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new …See details»